Clinical Trial

FRIEND: Fibroids and Unexplained Infertility Treatment With Epigallocatechin Gallate; A Natural CompounD in Green Tea

Study acronym: FRIEND
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated March 23, 2026 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
The objective of this study is to determine the effect of low caffeine green tea extract containing 45% epigallocatechin gallate (EGCG) on fibroids and subsequent pregnancy and live births in women seeking fertility treatment. The population will consist of 50 women desirous of conceiving, ages ≥18 to ≤40 years (at time of consent), and known to have class 2-6 fibroids, according to the FIGO staging system.
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2022-05-03; most recent amendment 2026-03-18.
Status change: Recruiting → Active, Not Recruiting 2026-03-18
Status change: Not Yet Recruiting → Recruiting 2022-09-07
Trial Details
NCT Number NCT05364008
Lead Sponsor Yale University
Collaborators: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), University of Chicago, University of Illinois at Chicago, Johns Hopkins University
Conditions Leiomyoma, Uterine
Enrollment 33 participants
Start Date 2023-01-05
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-23